User profiles for ANWAAR SAEED

Anwaar Saeed

University of Pittsburgh Medical Center (UPMC) & UPMC Hillman Cancer Center
Verified email at upmc.edu
Cited by 1998

Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis

…, S Abbasi, S Handa, R Al-Rajabi, A Saeed… - JAMA network …, 2020 - jamanetwork.com
Importance Standard therapy for locally advanced rectal cancer includes concurrent
chemoradiotherapy followed by surgery and adjuvant chemotherapy (CRT plus A). An alternative …

[HTML][HTML] The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the …

A Saeed, R Park, W Sun - Journal of Hematology & Oncology, 2021 - Springer
Several targeted therapies have shown efficacy in patients with advanced gastric cancer (GC)
and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic …

[HTML][HTML] Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis …

…, L Wade, W Sun, J Baranda, R Al-Rajabi, A Saeed… - BMC cancer, 2020 - Springer
Background PARP inhibitors (PARPi) have recently been approved for various malignancies
based on the results of several clinical trials. However, these trials have mostly recruited …

Biologics, immunotherapy, and future directions in the treatment of advanced cholangiocarcinoma

A Saeed, R Park, M Al-Jumayli, R Al-Rajabi… - Clinical Colorectal …, 2019 - Elsevier
Gemcitabine plus cisplatin remains the standard first-line systemic therapy for advanced
cholangiocarcinoma and offers a median survival of approximately 1 year. No standard …

[HTML][HTML] Immuno-oncotherapeutic approaches in advanced hepatocellular carcinoma

R Park, F Eshrat, M Al-Jumayli, A Saeed, A Saeed - Vaccines, 2020 - mdpi.com
Advanced hepatocellular carcinoma has limited treatment options, but there has been
extensive growth recently with cabozantinib, regorafenib, lenvatinib, nivolumab, atezolizumab, …

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real …

…, K Schulze, H Wege, VE Gaillard, A Saeed… - Hepatology, 2022 - journals.lww.com
Preliminary evidence of safety and tolerability of atezolizu... : Hepatology Preliminary
evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with …

Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline

…, A Nagarajan, H Park, A Saeed… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE To develop recommendations involving targeted therapies for patients with
advanced gastroesophageal cancer. METHODS The American Society of Clinical Oncology …

T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma

…, T Berg, L Rimassa, L Di Tommaso, A Saeed… - Journal of …, 2022 - Elsevier
Background & Aims Despite recent translation of immunotherapies into clinical practice, the
immunobiology of hepatocellular carcinoma (HCC), in particular the role and clinical …

Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort …

…, H Song, F Ye, R Irlmeier, N Debnath, A Saeed… - JAMA …, 2021 - jamanetwork.com
Importance Geriatric (aged ≥80 years) patients are historically underrepresented in cancer
clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in …

[HTML][HTML] Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical …

…, Y Gong, G Wei, D Szafron, E Sharon, A Saeed… - European Journal of …, 2021 - Elsevier
Purpose The development of treatment-related adverse events (trAE) correlates favorably
with clinical outcomes in multiple studies of patients receiving immune checkpoint inhibitors (…